Table 3.

Summary for immunogenicity of CABYR-a/b and CABYR-c in lung cancer

Type*Antibody of CABYR-a/b
Antibody of CABYR-c
Absorbance,No. positive/P
Absorbance,No. positive/P
mean (SD)no. testedχ2 testt testmean (SD)no. testedχ2 testt test
Healthy donor0.25 (0.08)0/600.24 (0.09)0/60
ADC0.24 (0.15)3/55>0.05>0.050.31 (0.14)3/55>0.05<0.01
SCC0.33 (0.24)11/82<0.01<0.050.32 (0.19)10/82<0.01<0.01
LCLC§0.16 (0.07)0/30.23 (0.08)0/3
SCLC0.33 (0.24)3/23<0.01>0.050.26 (0.15)1/23>0.05>0.05
ASC0.34 (0.21)1/6<0.01>0.050.39 (0.12)1/6<0.01<0.01
Other0.26 (0.17)1/5<0.01>0.050.32 (0.16)1/5<0.01>0.05
Total0.30 (0.21)19/174<0.01<0.050.31 (0.17)16/174<0.01<0.01
  • Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; LCLC, large cell lung carcinoma; SCLC, small cell lung carcinoma; ASC, adenosquamous carcinoma.

  • * Other, other types of lung cancer; Total, total number of patients.

  • χ2 test was used to assess the statistical significance of difference in ratios of sera-positive donors between patients and healthy donors.

  • Two-tailed Student's t test was used to assess the statistical significance of difference in absorbance values between patients and healthy donors.

  • § Sample size was too small for statistical analysis.